← boardnext 2027-12
GOSS
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.distress 5/10 · elevated risk$0.14-3%today-96% from 52w high
Lead: pulmonary arterial hypertension · est. market ~$25B (approx, global)
Revenue
$17M
Liquidity
$99M
Runway
0.6 yrs
Shares 1y
+3%
Price & events
-95.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.4%
1D
-18.1%
1W
-18.1%
1M
-62.5%
3M
-94.8%
6M
-92.5%
1Y
-86.9%
2Y
-98.1%
5Y
-98.6%
All
Overview
- Market Cap
- $32.88M
- Enterprise Value
- $-8.15M
- Volume
- 1.82M
- 52 Week Range
- $0.14 – $3.79
- Total Shares
- 234.70M
- Float Shares
- 137.91M
- Short %
- 11.14%
- % Held by Insiders
- 1.52%
- % Held by Institutions
- 73.64%
- RVOL
- 0.10x
- Beta
- 2.04
Pipeline stages · 1 programs
GB002 (seralutinib)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | GB002 (seralutinib) | Pulmonary Arterial Hypertension | — | active not recruiting |
Catalyst news & presentations · 5
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- promptly after Expiration Deadline, expected June 18, 2026readoutFinal settlement of exchange offer for remaining Existing Convertible NotesSEC 8-K
- February 2026readoutPhase 3seralutinib · Topline results from the Phase 3 PROSERA Study.SEC 8-K
- 2026-02-23enrollment delayseralutinib · Paused enrollment in SERANATA Study to evaluate PROSERA resultsSEC 8-K
- June 16, 2025enrollment completesecondaryPhase 3seralutinib · Completed enrollment for the global registrational Phase 3 PROSERA Study in Functional Class II and III PAH patients.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $4 (+2652% upside) · 5 analysts
- 2026-06-25HC Wainwright & Co.Buy
- 2026-05-26HC Wainwright & Co.Buy
- 2026-05-19BarclaysUnderweight
- 2026-03-23Cantor FitzgeraldOverweight → Neutral
- 2026-03-06HC Wainwright & Co.Buy
- 2026-03-05OppenheimerOutperform
Competitors — pulmonary arterial hypertension
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- PFEPFIZER INC$142.2B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- INSMINSMED Inc$22.9B · D2
- UTHRUNITED THERAPEUTICS Corp$22.3B · D0
- XOMAPXOMA Royalty Corp$313M · D1
- IKTInhibikase Therapeutics, Inc.$289M · D4
- KROSKeros Therapeutics, Inc.$197M · D2
Recent news
- 2026-07-22ETFs Investing in Gossamer Bio, Inc. Stocks - TradingView
- 2026-07-21GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
- 2026-07-20Goss’ bond increased to $1 million in downtown stabbing death - The Electric
- 2026-07-20Marilyn A. Goss Obituary (2026) - Erie, PA - Dusckas Funeral Home and Cremations Services, Inc. - Wesleyville - Legacy | Obituary Search
- 2026-07-20South Africa steps up action as Goss’s Wilt spreads to more maize growing regions - Milling Middle East & Africa
- 2026-07-19Harold Westcom Obituary Jul 19, 2026 - Goss Funeral Services
- 2026-07-18John Cavazos Obituary Apr 25, 2026 - Goss Funeral Services
- 2026-07-18Ethan Goss - Professional Fighters League
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.